A new COVID vaccine is 66 percent effective — but how much does vaccine efficacy matter?
Raw Story -

Last week, Novavax released results from its COVID-19 vaccine trials that are raising concerns in the United States as new, more transmissible — and perhaps more deadly — variants emerge. In Britain, where a more transmissible strain known as s B.1.1.7 is the dominant strain, the two-dose vaccine had an efficacy rate of nearly 89.4 percent. But in South Africa, where the strain B.1.351 is predominantly circulating, the efficacy rate decreased to 50 percent.

This article first appeared in...

Read this story at


Related Articles